{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T07:14:25Z","timestamp":1763968465732,"version":"3.41.2"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T00:00:00Z","timestamp":1629676800000},"content-version":"vor","delay-in-days":234,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The systemic autoinflammatory diseases are rare conditions; to date, data on coronavirus disease 2019 (COVID-19) infection and vaccination safety are scarce. Agents targeting innate immune pathways have transformed the management of affected patients, and their outcomes are of wider interest given the role of inflammation in both viral clearance and severe COVID-19 disease. We surveyed patients with systemic autoinflammatory disease on biologic therapy to determine the prevalence and outcomes of COVID-19 infection and to gather early safety data on vaccination.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Electronic medical records of 248 patients with systemic autoinflammatory disease on biologic therapy at a national centre were reviewed. Patients were then surveyed in clinic or using a Web-based survey.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In the cohort of 248 patients, no deaths were recorded. One hundred and seventy-five survey responses were received. Among the respondents, 27 reported suspected COVID-19 infection, of which 14 were confirmed by testing (8.0%). Two patients required hospital admission owing to dehydration. No patient required respiratory support or intensive care. One hundred and thirty-eight doses of COVID-19 vaccine had been administered to 130 patients. Side effects were reported after 71 of 138 (51.4%) administrations and were consistent with a flare of the underlying disease in 26 of 138 (18.8%) instances. No serious adverse events or hospital admissions were reported after vaccination.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>These data, including the largest published series of patients on anti-IL-1\/6 biologics to receive any adenoviral vector or messenger RNA vaccine, show no serious early concerns regarding vaccination and will provide an urgently needed resource to inform decision-making of these patients and their clinicians.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rap\/rkab043","type":"journal-article","created":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T13:53:04Z","timestamp":1629726784000},"source":"Crossref","is-referenced-by-count":19,"title":["COVID-19 and autoinflammatory diseases: prevalence and outcomes of infection and early experience of vaccination in patients on biologics"],"prefix":"10.1093","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9682-8683","authenticated-orcid":false,"given":"Claire J","family":"Peet","sequence":"first","affiliation":[{"name":"CAPS and Autoinflammatory Diseases Treatment Service, National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital"},{"name":"Department of Medical and Molecular Genetics, King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charalampia","family":"Papadopoulou","sequence":"additional","affiliation":[{"name":"CAPS and Autoinflammatory Diseases Treatment Service, National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bella Ruth M","family":"Sombrito","sequence":"additional","affiliation":[{"name":"CAPS and Autoinflammatory Diseases Treatment Service, National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R","family":"Wood","sequence":"additional","affiliation":[{"name":"CAPS and Autoinflammatory Diseases Treatment Service, National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen J","family":"Lachmann","sequence":"additional","affiliation":[{"name":"CAPS and Autoinflammatory Diseases Treatment Service, National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,8,23]]},"reference":[{"key":"2021082807503775600_rkab043-B1"},{"key":"2021082807503775600_rkab043-B2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nrrheum.2013.174","article-title":"A clinical guide to autoinflammatory diseases: familial Mediterranean fever and next-of-kin","volume":"10","author":"Ozen","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"2021082807503775600_rkab043-B3","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1136\/annrheumdis-2015-207546","article-title":"Recommendations for the management of auto-inflammatory diseases","volume":"74","author":"ter Haar","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2021082807503775600_rkab043-B4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2021082807503775600_rkab043-B5","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1136\/annrheumdis-2020-219773","article-title":"EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs","volume":"80","author":"Bijlsma","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2021082807503775600_rkab043-B6","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/art.39482","article-title":"Brief report: severe inflammation following vaccination against Streptococcus pneumoniae in patients with cryopyrin-associated periodic syndromes","volume":"68","author":"Walker","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2021082807503775600_rkab043-B7","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1002\/art.39763","article-title":"The phenotype and genotype of mevalonate kinase deficiency: a series of 114 cases from the Eurofever registry","volume":"68","author":"Ter Haar","year":"2016","journal-title":"Arthritis Rheumatol"},{"year":"2020","author":"National Institute for Health and Care Excellence","key":"2021082807503775600_rkab043-B8"},{"key":"2021082807503775600_rkab043-B9","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1136\/annrheumdis-2020-218707","article-title":"Clinical course of COVID-19 in a cohort of 342 familial Mediterranean fever patients with a long-term treatment by colchicine in a French endemic area","volume":"80","author":"Bourguiba","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2021082807503775600_rkab043-B10","doi-asserted-by":"crossref","DOI":"10.1002\/art.41702","article-title":"Commentary on \u201cUse of Anakinra to Prevent Mechanical Ventilation in Severe COVID-19: A Case Series.\u201d: COVID-19 disease in patients with recurrent pericarditis during treatment with anakinra","author":"Negro","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2021082807503775600_rkab043-B11","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"2021082807503775600_rkab043-B12","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"}],"container-title":["Rheumatology Advances in Practice"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumap\/advance-article-pdf\/doi\/10.1093\/rap\/rkab043\/39846971\/rkab043.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumap\/article-pdf\/5\/2\/rkab043\/40076436\/rkab043.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumap\/article-pdf\/5\/2\/rkab043\/40076436\/rkab043.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T07:50:49Z","timestamp":1630137049000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumap\/article\/doi\/10.1093\/rap\/rkab043\/6356533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,5,4]]}},"URL":"https:\/\/doi.org\/10.1093\/rap\/rkab043","relation":{},"ISSN":["2514-1775"],"issn-type":[{"type":"electronic","value":"2514-1775"}],"subject":[],"published-other":{"date-parts":[[2021]]},"published":{"date-parts":[[2021]]},"article-number":"rkab043"}}